Skip to main content
. Author manuscript; available in PMC: 2012 Sep 1.
Published in final edited form as: Curr Opin Virol. 2011 Sep 1;1(3):204–210. doi: 10.1016/j.coviro.2011.05.007

Figure 4.

Figure 4

Post-exposure administration of an anti-retroviral drug or NAbs. (a) A 4-week course of the reverse transcriptase inhibitor, tenofovir, was initiated in 6 animals, 48h following IV inoculation of 100 TCID50 of SIVmac239 (colored curves). Two untreated monkeys (black curves) served as controls (adapted from reference [41]). (b) Polyclonal anti-viral NAbs were transferred at 6h (four macaques) or 24h (2 macaques) post IV inoculation of SHIVDH12 (75 TCID50). The dashed curves represent two recipients of non-neutralizing antibodies (adapted from reference [41]).